Pasithea Therapeutics Corp. Executive Compensation and Stock Option Awards

On October 24, 2025, Pasithea Therapeutics Corp. announced changes to executive compensation and approved new stock option awards. The Board of Directors increased the base salary of CEO Dr. Tiago Reis Marques to $533,000 and decreased his target bonus percentage to 55% of annual base salary. CFO Daniel Schneiderman's base salary was increased to $391,000, with a target bonus percentage of 40%. The Board also approved stock option awards for executive officers and employees, with options to purchase shares at $0.715 per share, the closing price on the grant date. Non-employee directors received annual stock option awards, and the Chair of the Audit Committee's annual cash retainer was increased by $5,000. The Chair of the Board's total annual cash compensation was reduced from $100,000 to $35,000. Additionally, the Board approved a one-time stock option award for Prof. Lawrence Steinman and amended his consulting agreement to reduce payments from $25,000 to $1.00 per quarter.